Search research articles
Contact Us
Filters
Showing results (21-30 of 27) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 27 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 14, 2021
Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer
Christos Fountzilas, David L Bajor, Sarbajit Mukherjee, et al.
Cancer Research
|
September 10, 2020
5-Fluorouracil Enhances the Antitumor Activity of the Glutaminase Inhibitor CB-839 against <i>PIK3CA</i>-Mutant Colorectal Cancers
Yiqing Zhao, Xiujing Feng, Yicheng Chen, et al.
The Lancet. Oncology
|
May 4, 2023
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study
John H Strickler, Andrea Cercek, Salvatore Siena, et al.
Nature Communications
|
January 12, 2026
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2 + , RAS wild-type metastatic colorectal cancer (MOUNTAINEER): final analysis
John H Strickler, Andrea Cercek, Salvatore Siena, et al.
International Journal of Cancer
|
March 7, 2026
TP53 mutation is associated with improved disease control in patients with advanced RAS wild-type colorectal adenocarcinoma treated with cetuximab and pembrolizumab
Christos Fountzilas, Spencer Rosario, Agnieszka K Witkiewicz, et al.
Journal for Immunotherapy of Cancer
|
June 29, 2023
Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas
Andrew L Coveler, David C Smith, Tycel Phillips, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 11, 2021
Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer
Katelyn T Byrne, Courtney B Betts, Rosemarie Mick, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 27) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 27 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 14, 2021
Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer
Christos Fountzilas, David L Bajor, Sarbajit Mukherjee, et al.
Cancer Research
|
September 10, 2020
5-Fluorouracil Enhances the Antitumor Activity of the Glutaminase Inhibitor CB-839 against <i>PIK3CA</i>-Mutant Colorectal Cancers
Yiqing Zhao, Xiujing Feng, Yicheng Chen, et al.
The Lancet. Oncology
|
May 4, 2023
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study
John H Strickler, Andrea Cercek, Salvatore Siena, et al.
Nature Communications
|
January 12, 2026
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2 + , RAS wild-type metastatic colorectal cancer (MOUNTAINEER): final analysis
John H Strickler, Andrea Cercek, Salvatore Siena, et al.
International Journal of Cancer
|
March 7, 2026
TP53 mutation is associated with improved disease control in patients with advanced RAS wild-type colorectal adenocarcinoma treated with cetuximab and pembrolizumab
Christos Fountzilas, Spencer Rosario, Agnieszka K Witkiewicz, et al.
Journal for Immunotherapy of Cancer
|
June 29, 2023
Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas
Andrew L Coveler, David C Smith, Tycel Phillips, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 11, 2021
Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer
Katelyn T Byrne, Courtney B Betts, Rosemarie Mick, et al.
Page
of 3